Blood Disorders Market Analysis and Forecasts

Questions: Discounts, Updates etc.

Pages: 119

Price (Single): £1499

Price (Departmental): £2999

Price (Company): £4999

Publication Date: 2008-04-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This report breaks down therapies into four main groups:

 
In 2006 the authors of this report valued this market at $37 billion, but do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now? Will it increase in sales and bring in significant profits or will it be rocked by widespread patent expiration and ensuing generic competition? This report provides these answers, with detailed quantitative and qualitative analysis. This is information every player in the blood diseases treatments market should not be without.

Blood Disorders 2008 covers:

This study was achieved through research of relevant news, company reports, expert opinion, academic literature and gold-standard IMS databases. Financial forecasting based upon in-depth research was performed, with accompanying SWOT analyses. The result is a comprehensive market-based study with extensive analysis and informed opinion.

Table of Contents

Chapter 1: Executive Summary

 

Chapter 2: Blood Diseases and their Treatments

2.1 Functions of Blood

2.1.1 Haemopoiesis

2.1.2 Haemostasis

2.2 Anaemia

2.2.1 Iron Deficiency

2.2.2 Anaemia of Chronic Disease

2.2.3 Megaloblastic Anaemia

2.2.4 Pernicious Anaemia

2.2.5 Aplastic Anaemia

2.2.6 Haemolytic Anaemia

2.2.6.1 Inherited Haemolytic Anaemia: Hereditary Spherocytosis, Hereditary Elliptocytosis, Thalassaemia, Sickle Cell Disease and Glucose-6-phosphate Deficiency

2.2.6.2 Acquired Haemolytic Anaemia: Autoimmune Haemolytic Anaemia and Non-immune Haemolytic Anaemia

2.2.7 Anaemia and Aging

2.3 Myeloproliferative and Myelodysplastic Disorders

2.3.1 Polycythaemia: Polycythaemia Vera and Secondary Polycythaemia

2.3.2 Primary Thrombocythaemia

2.3.3 Primary Myelofibrosis (Myelosclerosis)

2.4 Bleeding Disorders

2.4.1 Autoimmune Thrombocytopenic Purpura

2.4.2 Inherited Coagulation Disorders

2.4.2.1 Haemophilia A

2.4.2.2 Haemophilia B

2.4.2.3 Von Willebrand's Disease

2.4.3 Acquired Coagulation Disorders

2.4.3.1 Disseminated Intravascular Coagulation

2.5 White Blood Cell Disorders

2.5.1 Neutropenia

2.6 Thrombosis

2.6.1 Arterial Thrombosis

2.6.2 Venous Thrombosis

 

Chapter 3: Blood Diseases Treatments

3.1 Antithrombotic Treatments

3.1.1 Platelet Aggregation Inhibitors

3.1.2 Anticoagulants Injectable

3.1.3 Anticoagulants Non-injectable

3.1.4 Fibrinolytics

3.1.5 Direct Thrombin Inhibitors

3.1.6 Antithrombin III and Other Protease Inhibitors

3.1.7 Other Antithrombotic Treatments

3.2 Anti-anaemic Treatments

3.2.1 Erythropoietin Products

3.2.2 Iron Replacement Therapy

3.2.3 Other Anti-anaemic Treatments

3.3 Clotting Factors

3.4 Other Treatments

 

Chapter 4: Blood Diseases Treatments World Market

4.1        Market Analysis

4.2        Market Shares

4.3        Top Ten Drugs

4.4        Percentage Change 2006-2013

 

Chapter 5: Antithrombotics Market

5.1 Market Analysis

5.2 The Platelet Aggregation Inhibitors Dominate the Antithrombotics Market

5.3 Drugs Generating below $300m dominate the Antithrombotics Market

5.4 Platelet Aggregation Inhibitors Market

5.5 Plavix Dominates the Platelet Aggregation Inhibitors Market

5.6 Plavix

5.6.1 Threat to Plavix’s Sales in 2006

5.6.2 Plavix’s Competitors

5.6.3 Plavix's Loss of Patent Protection

5.7 Clopidogrel Aptx's Withdrawal

5.8 Pletaal

5.8.1 Pletaal's Indications

5.8.2 Potential Market Expansion for Pletaal

5.9 Integrilin

5.9.1 The Leading Glycoprotein IIb/IIIa Receptor Inhibitor

5.9.2 Integrilin's Competitors

5.9.3 Potential Market Expansion for Integrilin

5.10 Injectable Anticoagulants Market

5.11 Lovenox Dominates the Injectable Anticoagulants Market

5.12 Lovenox

5.12.1 A Leading Low Molecular Weight Heparin

5.12.2 Lovenox's Loss of Patent Protection in 2012

5.12.3 Potential Market Expansion for Lovenox

5.12.4 Lovenox's Competitors

5.13 Fraxiparine

5.14 Fragmin

5.15 Other Anti-thrombotics

 

Chapter 6: Anti-anaemics World Market

6.1 Market Analysis

6.2 Erythropoietin Products Dominate the Anti-anaemics Market

6.3 Aranesp Dominates the Anti-anaemics Market

6.4 Erythropoietin Products

6.5 Aranesp Dominates the Erythropoietin Products Market

6.6 Aranesp

6.6.1 Fears over Erythropoietin Products Overuse

6.6.2 Scope for Expansion of Aranesp’s Indications

6.6.3 Aranesp’s Edge over Competitors

6.6.4 Other Competitiors of Aranesp                   

6.6.5 Entry of Erythropoietin Biosimilars in Europe

6.7 Erypo

6.7.1 Generic versions of Erypo

6.8 Epogen

6.9 NeoRecormon

6.10 Espo

6.11 Iron Replacement Therapy

6.12 Drugs with Revenues less than $300m Dominate the Iron Replacement Therapy Market

6.13 Venofer

6.14 Other Anti-Anaemics

 

Chapter 7: Clotting Factors Market

7.1 Market Analysis

7.2 Novoseven's Change in Market Share

7.3 NovoSeven

 

Chapter 8: Forces Affecting the Blood Diseases Treatments Market

8.1 SWOT Analysis of the Blood Diseases Treatments Market

8.2 Market Drivers

8.3 Market Restraints

8.4 Plavix and Parallel Trade

8.5 Strong developmental Pipeline for Drugs on     Parr with Lovenox

8.6 Ongoing Fears Over the use of Erythropoietin Products in Cancer Patients

8.7 FDA Approves New Haemophilia Treatment

 

Chapter 9: Geographical Breakdown of the Blood Diseases Treatments Market

9.1 The US Holds over 50% Market Share of the Blood Diseases Treatments Market

9.2 Increasing Market Share of Developing Countries at the Cost of Developed Countries

 

Chapter 10: Pipeline Products

10.1 Anti-thrombotics in the Pipeline

10.2 Anti-Anaemics in the Pipeline

10.3 Clotting Factors in the Pipeline

10.4 Other Blood Diseases Treatments in the Pipeline

 

Chapter 11: Conclusion

11.1 Blood Diseases and Treatments

11.2 Blood Diseases Treatments World Market

11.3 Blood Diseases Treatments Market Segments

11.4 Issues and Opportunities

11.5 Products in Development

11.6 Geographical Breakdown of the Market

11.7 Afterword

 

List of Tables

 

List of Figures

 

Organisations Mentioned in this Report

Other users found this report page using the following search terms: Antithrombotics Anti-anaemics Clotting Factors thrombosis anemia clotting market share blood erythropoietin analysis disorders 2008 lovenox sales plavix

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.